FAF
WST icon

Fjarde Ap-fonden’s West Pharmaceutical WST Stock Holding History

Fjarde Ap-fonden’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
29,600
-1,000
-3% -$306K 0.05% 294
2026
Q1 		$7.67M Buy
30,600
+10,990
+56% +$2.73M 0.04% 345
2025
Q4 		$5.4M Sell
19,610
-300
-2% -$82.1K 0.05% 324
2025
Q3 		$5.22M Buy
19,910
+910
+5% +$221K 0.05% 320
2025
Q2 		$4.16M Buy
19,000
+3,900
+26% +$834K 0.04% 362
2025
Q1 		$3.38M Buy
15,100
+2,000
+15% +$551K 0.04% 369
2024
Q4 		$4.29M Sell
13,100
-3,300
-20% -$1.04M 0.04% 367
2024
Q3 		$4.92M Buy
+16,400
New +$5.02M 0.05% 343
2024
Q1 		$5.58M Buy
14,100
+1,109
+9% +$410K 0.06% 318
2023
Q4 		$4.57M Sell
12,991
-300
-2% -$106K 0.06% 349
2023
Q3 		$4.99M Sell
13,291
-1,600
-11% -$619K 0.07% 312
2023
Q2 		$5.7M Buy
14,891
+3,500
+31% +$1.25M 0.07% 288
2023
Q1 		$3.95M Sell
11,391
-2,900
-20% -$847K 0.05% 360
2022
Q4 		$3.36M Buy
14,291
+710
+5% +$168K 0.05% 386
2022
Q3 		$4.11M Hold
13,581
– – 0.05% 383
2022
Q2 		$4.11M Buy
13,581
+2,500
+23% +$813K 0.05% 383
2022
Q1 		$4.55M Sell
11,081
-3,900
-26% -$1.53M 0.04% 408
2021
Q4 		$7.03M Sell
14,981
-1,600
-10% -$689K 0.06% 318
2021
Q3 		$7.04M Sell
16,581
-2,473
-13% -$1.04M 0.06% 309
2021
Q2 		$6.84M Buy
19,054
+2,000
+12% +$661K 0.06% 326
2021
Q1 		$4.8M Sell
17,054
-1,300
-7% -$372K 0.04% 421
2020
Q4 		$5.2M Buy
18,354
+4,400
+32% +$1.23M 0.05% 363
2020
Q3 		$3.84M Buy
13,954
+100
+0.7% +$26.5K 0.04% 415
2020
Q2 		$3.15M Sell
13,854
-3,446
-20% -$677K 0.04% 437
2020
Q1 		$2.63M Sell
17,300
-100
-0.6% -$15.4K 0.04% 419
2019
Q4 		$2.62M Buy
+17,400
New +$2.53M 0.03% 514

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fjarde Ap-fonden's WST Position: Q2 2026 in Review

Fjarde Ap-fonden reduced its West Pharmaceutical (WST) stake by 3.3% in Q2 2026, selling an estimated $306K and leaving 29,600 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #294.

Fjarde Ap-fonden first reported a position in WST in Q4 2019 and has held it in 26 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Fjarde Ap-fonden held 29,600 shares of West Pharmaceutical worth $10.6M as of Q2 2026.
  • Fjarde Ap-fonden sold 1,000 West Pharmaceutical shares in Q2 2026, an estimated $306K.
  • West Pharmaceutical made up 0.05% of Fjarde Ap-fonden's portfolio in Q2 2026, its #294 holding.
  • Fjarde Ap-fonden first reported a position in West Pharmaceutical in Q4 2019 and has held it in 26 quarters since.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.